Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1957 1
1963 6
1964 2
1965 1
1966 1
1973 1
1975 3
1976 1
1977 2
1979 6
1980 2
1981 7
1982 6
1983 4
1984 11
1985 17
1986 16
1987 12
1988 15
1989 32
1990 27
1991 17
1992 26
1993 29
1994 38
1995 35
1996 45
1997 44
1998 47
1999 42
2000 64
2001 55
2002 73
2003 122
2004 146
2005 160
2006 161
2007 155
2008 149
2009 152
2010 187
2011 180
2012 224
2013 263
2014 355
2015 326
2016 354
2017 410
2018 520
2019 591
2020 644
2021 810
2022 892
2023 863
2024 997
2025 1225
2026 289

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9,808 results

Results by year

Filters applied: . Clear all
Page 1
Infection-Related Preterm Birth.
Fan S, Li Q, Feng Q, Zhao P, Zhang X. Fan S, et al. Matern Fetal Med. 2025 Jul;7(3):172-180. doi: 10.1097/FM9.0000000000000288. Epub 2025 Apr 14. Matern Fetal Med. 2025. PMID: 41608213 Free PMC article. Review.
PXR activation ameliorates hyperuricemic nephropathy via NRF2 signaling.
Wu T, Li L, Chen Y, Ye W, Guo Z, Liang F, Zhou W, Yang Z, Zheng F, Liao H, Bi G, Yang X, Fan S, Fang JH, Pang J, Bi H. Wu T, et al. Among authors: fan s. Pharmacol Res. 2025 Dec;222:108039. doi: 10.1016/j.phrs.2025.108039. Epub 2025 Nov 17. Pharmacol Res. 2025. PMID: 41260532 Free article.
Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial.
Lu S, Wang J, Yang N, Lv D, Chen L, Wu L, Li X, Sun L, Yu Y, Jin B, Yang L, Guo Y, Xu H, Yi T, Zeng A, Dong X, Chen J, Wang Z, Niu H, Cheng Y, Pan P, Deng P, Pan H, Min X, Bai J, Liu L, Zhang T, Li J, Fan S, Shi MM, Mok T, Su W; SACHI Study Group. Lu S, et al. Among authors: fan s. Lancet. 2026 Jan 24;407(10526):375-387. doi: 10.1016/S0140-6736(25)01811-2. Epub 2026 Jan 13. Lancet. 2026. PMID: 41544643 Clinical Trial.
9,808 results